J&J's Poon retiring

Share this article:
J&J's Poon retiring
J&J's Poon retiring
Christine Poon, vice chairman of the board of directors and worldwide chairman, pharmaceuticals group at Johnson & Johnson, will retire in March after almost a quarter-century in the healthcare industry and eight years with J&J. The company did not name a successor to Poon.
    
In a company press release, J&J chairman and CEO William C. Weldon, said: “Chris has been instrumental in helping to build Johnson & Johnson's pipeline of medicines to its place today as one of the world's most highly regarded. We will certainly miss Chris' counsel, her leadership focus in building our pharmaceuticals business and her constant quest to bring better health and well-being to people around the world. She has exhibited strong leadership and personal involvement in building a skilled and diverse workforce. As a member of our executive committee and vice chairman, Chris has helped to shape Johnson & Johnson's strategy and vision for the future."
    
Poon's career with J&J began in November 2000, as company group chairman, pharmaceuticals. In 2001, she was promoted to the executive committee and named worldwide chairman, pharmaceuticals. Poon was appointed worldwide chairman, medicines & nutritionals, in October 2003, and was elected to the company's board of directors and named a vice chairman of the board in 2005.

Before joining Johnson & Johnson, Poon spent 15 years at Bristol-Myers Squibb, where she was president of international medicines. Poon is on the board of directors of Prudential Financial, in Newark, NJ, and the Fox Chase Cancer Center in Philadelphia, PA.

Poon is on the advisory board of the Healthcare Businesswomen's Association (HBA) and was named HBA's Woman of the Year in 2004.     
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...